Vaginitis (Bacterial)

Bacterial vaginosis is the most common cause of abnormal vaginal discharge in reproductive-age women, accounting for 40–50% of identified vaginitis cases. [1-2] It represents a vaginal dysbiosis — not a true infection or inflammatory state — characterized by replacement of normal Lactobacillus-dominant flora with anaerobic organisms including Gardnerella vaginalis, Prevotella, Bacteroides, and Atopobium vaginae. [3] It generates approximately 5–10 million office visits annually. [1]

The following diagnostic algorithm from the AAFP provides a practical framework for evaluating vaginal complaints:

1. History

• Discharge characteristics: Thin, homogeneous, grayish-white discharge that smoothly coats vaginal walls [1][4]
• Odor: "Fishy" amine odor, classically worse after intercourse and during menses [3]
• Timing/triggers: Onset relative to menses, new sexual partner, douching, recent antibiotic use
• Severity/progression: Chronic or recurrent episodes (≥3 documented episodes/year = recurrent BV) [3]
• Associated symptoms: Mild vulvovaginal irritation or burning; significant pruritus is uncommon and suggests candidiasis [1]
• Important negatives: Absence of significant pruritus, dysuria, deep pelvic pain, fever, or purulent discharge helps distinguish BV from other etiologies [5]

2. Alarm Features

• Fever, cervical motion tenderness, adnexal mass/tenderness → consider PID, tubo-ovarian abscess, ectopic pregnancy [1]
• Purulent cervical discharge with WBCs → consider cervicitis (chlamydia, gonorrhea) [6]
• Pregnancy with BV → associated with 2-fold increased risk of preterm birth, PROM, chorioamnionitis, and postpartum endometritis [7-8]
• Bloody or foul-smelling discharge in postmenopausal patients → rule out malignancy, foreign body, atrophic vaginitis

3. Medications

First-line treatment (CDC 2021 / ACOG): [3][6]

• Metronidazole 500 mg PO BID × 7 days
• Metronidazole gel 0.75% — one applicator (5 g) intravaginally daily × 5 days
• Clindamycin cream 2% — one applicator (5 g) intravaginally at bedtime × 7 days

Alternative regimens: [6]

• Secnidazole 2 g PO single dose
• Tinidazole 2 g PO daily × 2 days, or 1 g PO daily × 5 days
• Clindamycin 300 mg PO BID × 7 days
• Clindamycin ovules 100 mg intravaginally at bedtime × 3 days

Recurrent BV suppression: Metronidazole gel 0.75% twice weekly × 16 weeks after acute treatment [3][9]

Key medication notes:

• The CDC 2021 guidelines note that evidence for a disulfiram-like reaction with metronidazole and alcohol is lacking; refraining from alcohol during metronidazole use is considered unnecessary per the CDC, though manufacturers still recommend avoidance [6]
• Clindamycin cream is oil-based and may weaken latex condoms/diaphragms for 5 days after use [6]
• In pregnancy: Oral metronidazole 500 mg BID × 7 days or 250 mg TID × 7 days; tinidazole should be avoided; data insufficient for secnidazole in pregnancy [6]

4. Diet

• No specific dietary triggers are established for BV
• Avoidance of vaginal douching is strongly recommended, as it disrupts normal flora and increases recurrence risk [6]
• Adequate hydration and general nutritional health support immune function

5. Review of Systems

• GU: Vaginal discharge character, odor, dyspareunia, dysuria, urinary frequency
• GYN: Menstrual history, intermenstrual bleeding, postcoital bleeding
• GI: Abdominal/pelvic pain (to rule out PID)
• Constitutional: Fever, chills, malaise (suggests ascending infection)
• Dermatologic: Vulvar rash, lesions, ulcers (to rule out HSV, contact dermatitis)

6. Collateral History and Family History

• Sexual history: Number of partners, new partners, sex of partners (BV occurs in both heterosexual and same-sex female couples), condom use [3]
• Partner symptoms: Emerging evidence supports sexual transmission; the StepUp RCT demonstrated that concurrent male partner treatment (oral metronidazole + topical penile clindamycin × 7 days) reduced BV recurrence from 63% to 35% at 12 weeks [10]
• Hygiene practices: Douching, use of scented products, intrauterine device use
• Family history is not a major contributor, though genetic polymorphisms (e.g., TNF-α SNPs) may modulate risk of BV-associated preterm birth [7]

7. Risk Factors

• Sexual activity (new or multiple partners, female-female sexual contact) [3]
• Douching [3]
• Black, Hispanic, and Mexican American race/ethnicity (higher prevalence) [3]
• IUD use [10]
• Lack of condom use [11]
• Smoking [11]
• Prior history of BV (strongest predictor of recurrence) [3]
• Uncircumcised male partner [10]

8. Differential Diagnosis

• Vulvovaginal candidiasis — thick, white, curd-like discharge; pruritus predominant; pH ≤4.5; KOH shows hyphae/budding yeast [1]
• Trichomoniasis — green/yellow frothy discharge; strawberry cervix; motile trichomonads on wet mount; pH >4.5 [1]
• Cervicitis (chlamydia, gonorrhea) — mucopurulent cervical discharge, WBCs on wet mount without clue cells [6]
• Desquamative inflammatory vaginitis — purulent discharge, vaginal erythema, parabasal cells on microscopy [5]
• Atrophic vaginitis — thin, dry mucosa in postmenopausal patients; pH elevated [5]
• Irritant/allergic vaginitis — exposure history to soaps, spermicides, latex [3]
• PID — must-not-miss; fever, CMT, adnexal tenderness [1]
• Foreign body — foul-smelling discharge, often unilateral

9. Past Medical History

• Prior episodes of BV and treatments used (response, recurrence pattern)
• History of STIs (chlamydia, gonorrhea, trichomoniasis, HIV)
• Pregnancy history, prior preterm births
• Recent gynecologic procedures (increased risk of postprocedural infection with BV) [3]
• Chronic conditions: HIV (higher BV prevalence), diabetes

10. Physical Exam

• Vitals: Fever suggests ascending infection (PID, tubo-ovarian abscess)
• External genitalia: Typically normal in BV; erythema/excoriations suggest candidiasis or dermatitis
• Speculum exam: Thin, homogeneous, grayish-white discharge coating vaginal walls; no significant vaginal erythema or inflammation [3-4]
• Cervix: Should appear normal; mucopurulent discharge or friability suggests cervicitis
• Bimanual exam: No cervical motion tenderness or adnexal tenderness (if present, evaluate for PID)

11. Lab Studies

• Vaginal pH >4.5 (sensitivity 97%, specificity 64%) [12]
• KOH whiff test — fishy amine odor with 10% KOH
• Wet mount saline microscopy — clue cells (>20% of epithelial cells); absence of WBCs and trichomonads
• Gram stain with Nugent scoring — reference standard (score 7–10 = BV) [3][6]
• NAAT — available for BV, candida, and trichomoniasis; useful when microscopy is unavailable [1][13]
• STI testing — CDC recommends concurrent testing for HIV and other STIs in patients with BV [3]
• Routine bacterial culture is NOT recommended (G. vaginalis is a commensal in ~50% of healthy women) [3]

The following table summarizes diagnostic test performance for vaginitis:

12. Imaging

• Not indicated for uncomplicated BV
• Pelvic ultrasound if concern for tubo-ovarian abscess, ectopic pregnancy, or adnexal pathology based on exam findings

13. Special Tests

Amsel Criteria (≥3 of 4 required for diagnosis): [3]

• Thin, homogeneous, white-gray discharge
• Clue cells >20% on saline microscopy
• Vaginal pH >4.5
• Positive KOH whiff test

Sensitivity 92%, specificity 77% compared to Nugent scoring. [3] Clue cells are the single most reliable indicator. [3]

Point-of-care tests: [6]

• OSOM BV Blue (vaginal sialidase activity): sensitivity 90%, specificity >95%
• Affirm VP III (G. vaginalis DNA probe): sensitivity 97% when combined with pH and amine odor

Multiplex vaginal panels (NAAT-based) — FDA-cleared panels can simultaneously detect BV, candida, and trichomoniasis [13]

14. ECG

15. Assessment

• BV is a noninflammatory vaginal dysbiosis, not a true infection; it does not cause significant mucosal inflammation [3]
• Approximately 50% of women with BV are asymptomatic [4][14]
• Self-diagnosis is unreliable — ACOG recommends against it due to overlapping symptoms with other causes of vaginitis [3]
• Complications: Increased susceptibility to HIV, HSV-2, chlamydia, gonorrhea, and trichomoniasis; PID; postprocedural gynecologic infections [3][7]
• In pregnancy: 2-fold increased risk of preterm birth (OR 1.76–2.19), PROM (OR 2.59), miscarriage (OR 2.34), and postpartum endometritis [7-8]
• Recurrence is the major clinical challenge: up to 50% recur within 12 months [3][9]

16. Treatment Plan

Initial treatment — treat symptomatic patients only; asymptomatic screening/treatment is not recommended (USPSTF): [6][15]

• Metronidazole 500 mg PO BID × 7 days (most commonly used) [6]
• Metronidazole gel 0.75% intravaginally daily × 5 days (better GI tolerability) [3]
• Clindamycin cream 2% intravaginally at bedtime × 7 days [6]

Recurrent BV (≥3 episodes/year): [3][9]

• Extended metronidazole 500 mg BID × 10–14 days
• Followed by suppressive metronidazole gel 0.75% twice weekly × 3–6 months

Male partner treatment for recurrent BV — the landmark StepUp trial (NEJM 2025) demonstrated that concurrent male partner treatment with oral metronidazole 400 mg BID + topical 2% clindamycin cream to penile skin BID × 7 days reduced BV recurrence from 63% to 35% at 12 weeks (HR 0.37; 95% CI, 0.22–0.61; P<0.001). [10] ACOG now advises considering partner therapy for recurrent BV. [16]

Pregnancy: Treat all symptomatic pregnant women; oral metronidazole is safe in pregnancy [6]

Counseling: Avoid douching; use condoms or abstain during treatment; avoid tampons with intravaginal products [3][6]

17. Disposition

• Discharge — the vast majority of BV cases are managed entirely as outpatients
• Admission criteria — only if concurrent PID with systemic toxicity, tubo-ovarian abscess, or inability to tolerate oral medications
• Specialist referral:
  • OB/GYN for recurrent BV refractory to suppressive therapy
  • Infectious disease if concern for resistant organisms or complex coinfections
  • MFM if pregnant with recurrent BV and history of preterm birth

18. Follow Up / Return Precautions

• Routine follow-up/test of cure is not necessary if symptoms resolve [3]
• Retest within 3 months if symptoms recur (recurrence rate up to 30% at 3 months) [3]
• Return precautions — advise patients to return for:
  • Persistent or worsening symptoms after completing treatment
  • New fever, pelvic pain, or abnormal bleeding (concern for PID)
  • Recurrent episodes (≥3/year warrants suppressive therapy discussion)
• Expected course: Symptoms typically improve within 2–3 days of starting treatment; full resolution by end of therapy
• Patient counseling: BV is not a classic STI but is associated with sexual activity; partner treatment may be discussed for recurrent cases; avoid douching; complete full course of antibiotics

References

1. Vaginitis: Diagnosis and Treatment. — Geer K, Klega A. American Family Physician. 2025.

2. Vaginitis: Diagnosis and Treatment. — Geer K, Klega A. American Family Physician. 2025.

3. Vaginitis: Diagnosis and Treatment. — Geer K, Klega A. American Family Physician. 2025.

4. Vaginitis: Diagnosis and Treatment. — Paladine HL, Desai UA. American Family Physician. 2018.

5. Vaginitis: Diagnosis and Treatment. — Paladine HL, Desai UA. American Family Physician. 2018.

6. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2020.

7. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2020.

8. Fighting polymicrobial biofilms in bacterial vaginosis. — Sousa LGV, Pereira SA, Cerca N. Microbial Biotechnology. 2023.

9. Fighting polymicrobial biofilms in bacterial vaginosis. — Sousa LGV, Pereira SA, Cerca N. Microbial Biotechnology. 2023.

10. Noncandidal Vaginitis: A Comprehensive Approach to Diagnosis and Management. — Neal CM, Kus LH, Eckert LO, Peipert JF. American Journal of Obstetrics and Gynecology. 2020.

11. Noncandidal Vaginitis: A Comprehensive Approach to Diagnosis and Management. — Neal CM, Kus LH, Eckert LO, Peipert JF. American Journal of Obstetrics and Gynecology. 2020.

12. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.

13. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.

14. Bacterial Vaginosis and Desquamative Inflammatory Vaginitis. — Paavonen J, Brunham RC. The New England Journal of Medicine. 2018.

15. Bacterial Vaginosis and Desquamative Inflammatory Vaginitis. — Paavonen J, Brunham RC. The New England Journal of Medicine. 2018.

16. Systematic Review and Meta-Analysis of Maternal and Fetal Outcomes Among Pregnant Women With Bacterial Vaginosis. — Kenfack-Zanguim J, Kenmoe S, Bowo-Ngandji A, et al. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2023.

17. Systematic Review and Meta-Analysis of Maternal and Fetal Outcomes Among Pregnant Women With Bacterial Vaginosis. — Kenfack-Zanguim J, Kenmoe S, Bowo-Ngandji A, et al. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2023.

18. Characterization and Treatment of Recurrent Bacterial Vaginosis. — Faught BM, Reyes S. Journal of Women's Health. 2019.

19. Characterization and Treatment of Recurrent Bacterial Vaginosis. — Faught BM, Reyes S. Journal of Women's Health. 2019.

20. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. — Vodstrcil LA, Plummer EL, Fairley CK, et al. The New England Journal of Medicine. 2025.

21. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. — Vodstrcil LA, Plummer EL, Fairley CK, et al. The New England Journal of Medicine. 2025.

22. Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: US Preventive Services Task Force Recommendation Statement. — US Preventive Services Task Force, Owens DK, Davidson KW, et al. The Journal of the American Medical Association. 2020.

23. Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: US Preventive Services Task Force Recommendation Statement. — US Preventive Services Task Force, Owens DK, Davidson KW, et al. The Journal of the American Medical Association. 2020.

24. Acute Vulvovaginitis. — Eckert LO. The New England Journal of Medicine. 2006.

25. Acute Vulvovaginitis. — Eckert LO. The New England Journal of Medicine. 2006.

26. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

27. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

28. Screening for Bacterial Vaginosis in Pregnant Adolescents and Women to Prevent Preterm Delivery: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. — Kahwati LC, Clark R, Berkman N, et al. The Journal of the American Medical Association. 2020.

29. Screening for Bacterial Vaginosis in Pregnant Adolescents and Women to Prevent Preterm Delivery: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. — Kahwati LC, Clark R, Berkman N, et al. The Journal of the American Medical Association. 2020.

30. Sexually Transmitted Infections: Updates From the 2021 CDC Guidelines. — Dalby J, Stoner BP. American Family Physician. 2022.

31. Sexually Transmitted Infections: Updates From the 2021 CDC Guidelines. — Dalby J, Stoner BP. American Family Physician. 2022.

32. Advances in Treating Bacterial Vaginosis: Recognizing Sexual Transmission and Pipeline of Therapies. — Kim ES, Waltmann A, Duncan JA, Hood-Pishchany I. Current Opinion in Infectious Diseases. 2026.

33. Advances in Treating Bacterial Vaginosis: Recognizing Sexual Transmission and Pipeline of Therapies. — Kim ES, Waltmann A, Duncan JA, Hood-Pishchany I. Current Opinion in Infectious Diseases. 2026.